Cited by 869Computational Drug Discovery MethodsDrug Solubulity and Delivery SystemsChemical Synthesis and Analysis

The DOI matches its Crossref record; 289 of the 295 references it cites were found in a registry or an index.

Oral Druggable Space beyond the Rule of 5: Insights from Drugs and Clinical Candidates

Open access

Doak, Bradley Croy, Over, Bjӧrn, Giordanetto, Fabrizio, Kihlberg, Jan·2014·Chemistry & Biology

DOI 10.1016/j.chembiol.2014.08.013

Open this paper in CoChat — free account Open PDF

Abstract

The rule of 5 (Ro5) is a set of in silico guidelines applied to drug discovery to prioritize compounds with an increased likelihood of high oral absorption. It has been influential in reducing attrition due to poor pharmacokinetics over the last 15 years. However, strict reliance on the Ro5 may have resulted in lost opportunities, particularly for difficult targets. To identify opportunities for oral drug discovery beyond the Ro5 (bRo5), we have comprehensively analyzed drugs and clinical candidates with molecular weight (MW) > 500 Da. We conclude that oral drugs are found far bRo5 and properties such as intramolecular hydrogen bonding, macrocyclization, dosage, and formulations can be used to improve bRo5 bioavailability. Natural products and structure-based design, often from peptidic leads, are key sources for oral bRo5 drugs. These insights should help guide the design of oral drugs in bRo5 space, which is of particular interest for difficult targets.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.chembiol.2014.08.013

Cites

289 of 289 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings 1PII of original article: S0169-409X(96)00423-1. The article was originally published in Advanced Drug Delivery Reviews 23 (1997) 3–25. 1
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (1997) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(96)00423-1 · Cited by 11,484
Molecular properties that influence the oral bioavailability of drug candidates
Veber, D. F., Johnson, S. R., Cheng, H.-Y., Smith, B. R., Ward, K. W., & Kopple, K. D. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm020017n · Cited by 8,420
Lead- and drug-like compounds: the rule-of-five revolution
Lipinski, C. A. (2004) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2004.11.007 · Cited by 6,455
Escape from Flatland: Increasing Saturation as an Approach to Improving Clinical Success
Lovering, F., Bikker, J. A., & Humblet, C. C. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm901241e · Cited by 4,614
Can the pharmaceutical industry reduce attrition rates?
Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167
Drug-like properties and the causes of poor solubility and poor permeability
Lipinski, C. A. (2000) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/s1056-8719(00)00107-6 · Cited by 3,776
How to improve R&D productivity: the pharmaceutical industry's grand challenge
Paul, S. M., Mytelka, D. S., Dunwiddie, C. T., Persinger, C. C., Munos, B. H., Lindborg, S. R., & Schacht, A. L. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3078 · Cited by 3,566
Membrane transporters in drug development
The International Transporter Consortium, Giacomini, K. M., Huang, S.-M., Tweedie, D. J., Benet, L. Z., Brouwer, K. L. R., Chu, X., Dahlin, A., Evers, R., Fischer, V., et al. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3028 · Cited by 3,340
Fast Calculation of Molecular Polar Surface Area as a Sum of Fragment-Based Contributions and Its Application to the Prediction of Drug Transport Properties
Ertl, P., Rohde, B., & Selzer, P. M. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm000942e · Cited by 3,149

Flagged first, then by citations

Show all 295 references

6 of the 295 references couldn’t be matched to a known paper.

Research works printed but not linked: 1

Bilello, J.P., Dousson, C.B., Colla, M.L., Chapron, C., Bhadresa, S., Camire, M., Serra, I., Gillum, J.M., Lallos, L.B., McCarville, J.F., et al. (2011). Antiviral and Preclinical Profiles of HCV NS5A Inhibitors IDX380 and IDX719. Proceedings of the 18th International Symposium on Hepatitis C Virus and Related Viruses, Seattle; September 8–12, 2011.

Sorted by citations

Items 301–400 of 869

In Silico and In Vitro Evaluation of the Antimicrobial Potential of Bacillus cereus Isolated from Apis dorsata Gut against Neisseria gonorrhoeae
Niode, N. J., Adji, A., Rimbing, J., Tulung, M., Alorabi, M., El‐Shehawi, A. M., Idroes, R., Çelik, İ., Fatimawali, F., Adam, A. A., et al. (2021) · Antibiotics · doi:10.3390/antibiotics10111401 · Cited by 22
“The Ro5 analysis of fengycin, surfactin, and iturin A is summarized in Table 7.”
BackgroundInfluential
Insight into the corrosion inhibiting potential and anticancer activity of 1-(4-methoxyphenyl)-5-methyl-N’-(2-oxoindolin-3-ylidene)-1H-1,2,3-triazole-4-carbohydrazide via computational approaches
Oyeneyin, O. E., Ibrahim, A., Ipinloju, N., Ademoyegun, A. J., & Ojo, N. D. (2023) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2023.2260491 · Cited by 21
“This further confirms that the compound has a good oral bioavailability (Doak et al., 2014).”
Neue Methoden und Designprinzipien für zellgängige Peptide
Peraro, L., & Kritzer, J. A. (2018) · Angewandte Chemie · doi:10.1002/ange.201801361 · Cited by 22
Genetically Encoded Libraries of Constrained Peptides
Bosma, T., Rink, R., Moosmeier, M. A., & Moll, G. N. (2019) · ChemBioChem · doi:10.1002/cbic.201900031 · Cited by 21
Managing Experimental 3D Structures in the Beyond‐Rule‐of‐5 Chemical Space: The Case of Rifampicin
Ermondi, G., Lavore, F., Vallaro, M., Tiana, G., Vasile, F., & Caron, G. (2021) · Chemistry - A European Journal · doi:10.1002/chem.202100961 · Cited by 21
Compound Properties and their Influence on Drug Quality
Chen, H., Engkvist, O., & Kogej, T. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-417205-0.00015-8 · Cited by 22
The role and mechanisms of canonical and non-canonical tailoring enzymes in bacterial terpenoid biosynthesis
Kakumu, Y., Chaudhri, A. A., & Helfrich, E. J. N. (2025) · Natural Product Reports · doi:10.1039/d4np00048j · Cited by 21
A Novel Rheological Method to Assess Drug-Polymer Interactions Regarding Miscibility and Crystallization of Drug in Amorphous Solid Dispersions for Oral Drug Delivery
Τσακιρίδου, Γ., Reppas, C. I., Kuentz, M., & Kalantzi, L. (2019) · Pharmaceutics · doi:10.3390/pharmaceutics11120625 · Cited by 20
“In recent years, the pharmaceutical industry is pursuing less druggable targets, with characteristics such as increased size and flexibility [1,2].”
Background
Exploring the potentials of some compounds from Garcinia kola seeds towards identification of novel PDE‐5 inhibitors in erectile dysfunction therapy
Ojo, O. A., Ojo, A. B., Maimako, R. F., Rotimi, D., Iyobhebhe, M. E., Alejolowo, O. O., Nwonuma, C. O., & Elebiyo, T. (2021) · Andrologia · doi:10.1111/and.14092 · Cited by 20
“…that potential drugs that are in agreement with the rule of five, (RO5) like the compounds from this study, are likely to exhibit lower attrition rates in cases of clinical trials which could result to a higher possibility of getting to the open markets to be used as therapies (Doak et al., 2014).”
Background
Exploring phenylcarbamoylazinane-1,2,4-triazole thioethers as lipoxygenase inhibitors supported with in vitro, in silico and cytotoxic studies
Shahid, W., Ashraf, M., Saleem, M., Bashir, B., Muzaffar, S., Ali, M., Kaleem, A., Rehman, A.-U., Amjad, H., Bhattarai, K., et al. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.105261 · Cited by 20
Trust Your Gut: Strategies and Tactics for Intestinally Restricted Drugs
Dorel, R., Wong, A. R., & Crawford, J. J. (2023) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.3c00001 · Cited by 20
Evaluation of therapeutic potentials of selected phytochemicals against Nipah virus, a multi-dimensional in silico study
Rababi, D., & Nag, A. (2023) · 3 Biotech · doi:10.1007/s13205-023-03595-y · Cited by 20
Evaluating physiochemical properties of FDA-approved orally administered drugs
Reese, T. C., Devineni, A., Smith, T., Lalami, I., Ahn, J., & Raj, G. V. (2023) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2023.2275617 · Cited by 20
Combining empirical knowledge, in silico molecular docking and ADMET profiling to identify therapeutic phytochemicals from Brucea antidysentrica for acute myeloid leukemia
Bultum, L. E., Tolossa, G. B., & Lee, D. (2022) · PLoS ONE · doi:10.1371/journal.pone.0270050 · Cited by 25
“Especially over the past two decades, the increasing significance of drugs not conforming to this rule is illustrated by the increase in molecular mass of approved oral drugs, compelling evidence to contradict the suggestion that molecular weight is a “drug-like” property [76, 77], Since natural products contain enorm…”
Background
Interactive deciphering electron-shuttling characteristics of Coffea arabica leaves and potential bioenergy-steered anti-SARS-CoV-2 RdRp inhibitor via microbial fuel cells
Tsai, P., Tayo, L. L., Ting, J. U., Hsieh, C.-Y., Lee, C., Chen, C.-L., Yang, H.-C., Tsai, H.-Y., Hsueh, C., & Chen, B. (2022) · Industrial Crops and Products · doi:10.1016/j.indcrop.2022.115944 · Cited by 19
“proposed that the criteria for drug-likeness could be extended further than just the rule of five (Doak et al., 2014).”
Isolation, Characterization, Genome Annotation, and Evaluation of Tyrosinase Inhibitory Activity in Secondary Metabolites of Paenibacillus sp. JNUCC32: A Comprehensive Analysis through Molecular Docking and Molecular Dynamics Simulation
Xu, Y., Liang, X., & Hyun, C. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25042213 · Cited by 19
Small-Molecule Inhibitors of Protein–Protein Interactions
Liu, Z., Chen, H., Wold, E. A., & Zhou, J. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-409547-2.12326-1 · Cited by 19
Prediction Accuracy of Mechanism-Based Oral Absorption Model for Dogs
Akiyama, Y., Kimoto, T., Mukumoto, H., Miyake, S., Ito, S., Taniguchi, T., Nomura, Y., Matsumura, N., Fujita, T., & Sugano, K. (2019) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2019.03.015 · Cited by 19
Benchmark of Generic Shapes for Macrocycles
Romero, A. R., Ruiz-Moreno, A. J., Groves, M. R., Velasco-Velázquez, M. A., & Dömling, A. S. S. (2020) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.0c01038 · Cited by 18
Heterocycle-Based Multicomponent Reactions in Drug Discovery: From Hit Finding to Rational Design
Rodríguez, P. N., Ghashghaei, O., Bagán, A., Escolano, C., & Lavilla, R. (2022) · Biomedicines · doi:10.3390/biomedicines10071488 · Cited by 18
“The concern about the relevant chemical space in a given MedChem project, although capital, is often overlooked [8,9], considering that the dimension of drug-like space is around 1060 virtual molecules and, likely, we should go beyond this limit to find new medicines [10].”
Background
Structure-based scoring of anthocyanins and molecular modeling of PfLDH, PfDHODH, and PfDHFR reveal novel potential P. falciparum inhibitors
Akinnusi, P. A., Olubode, S. O., Adebesin, A. O., Osadipe, T. J., Nwankwo, D. O., Adebisi, A. D., Bisi-Adeniyi, T. I., Alo, Y. M., Owoloye, A. J., & Oyebola, K. M. (2023) · Informatics in Medicine Unlocked · doi:10.1016/j.imu.2023.101206 · Cited by 18
Design and Evaluation of a Low Hydrogen Bond Donor Count Fragment Screening Set to Aid Hit Generation of PROTACs Intended for Oral Delivery
Whitehurst, B. C., Bauer, M. R., Edfeldt, F., Gunnarsson, A., Margreitter, C., Rawlins, P. B., & Storer, R. I. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00493 · Cited by 18
An Elusive Target: Inhibitors of JC Polyomavirus Infection and Their Development as Therapeutics for the Treatment of Progressive Multifocal Leukoencephalopathy
Kaiserman, J., O’Hara, B. A., Haley, S. A., & Atwood, W. J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24108580 · Cited by 18
Water-soluble inhibitors of ABCG2 (BCRP) – A fragment-based and computational approach
Antoni, F., Wifling, D., & Bernhardt, G. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112958 · Cited by 18
Synthesis, Anticonvulsant, and Antinociceptive Activity of New 3-(2-Chlorophenyl)- and 3-(3-Chlorophenyl)-2,5-dioxo-pyrrolidin-1-yl-acetamides
Góra, M., Czopek, A., Rapacz, A., Gębska, A., Wójcik‐Pszczoła, K., Pękala, E., & Kamiński, K. (2021) · Molecules · doi:10.3390/molecules26061564 · Cited by 18
“Although Lipinski and Veber rules are guidelines for structural drug-likeness properties of compounds, recent research among existing drugs and drug candidates showed that many oral medications are found far beyond Lipinski rule; therefore, compounds which did not comply with all Veber or Lipinski rules should not be…”
Background
Comprehensive biological {DNA/RNA binding profile, cleavage &cytotoxicity activity} of structurally well-characterized chromone-appended Cu(II)(L1-3)(phen) potential anticancer drug candidates
Khursheed, S., Tabassum, S., & Arjmand, F. (2021) · Polyhedron · doi:10.1016/j.poly.2021.115638 · Cited by 18
CNS delivery of targeted protein degraders
Agarwal, P., Reid, D. L., & Amiji, M. M. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.06.057 · Cited by 19
Endocrine-Disrupting Effects of Salicylate Preservatives on Neurosteroidogenesis: Targeting 5α-Reductase Type 1
Li, W., Cui, R., Qi, S., Zheng, K., Yang, J., Ge, R., & Wang, Y. (2024) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.4c04265 · Cited by 17
Covalent Recruitment of NEDD4 for Targeted Protein Degradation: Rational Design of Small Molecular Degraders
He, X., Zeng, S., Wen, Y., Yang, T., Huang, C., Li, Y.-F., Zhang, Z., Ding, K., Liu, T., Tan, Y., et al. (2025) · Journal of the American Chemical Society · doi:10.1021/jacs.4c18083 · Cited by 20
Physicochemical Profiling and Comparison of Research Antiplasmodials and Advanced Stage Antimalarials with Oral Drugs
Bhanot, A., & Sundriyal, S. (2021) · ACS Omega · doi:10.1021/acsomega.1c00104 · Cited by 18
Current screening, design, and delivery approaches to address low permeability of chemically synthesized modalities in drug discovery and early clinical development
Yang, W., Lipert, M. P., & Nofsinger, R. (2023) · Drug Discovery Today · doi:10.1016/j.drudis.2023.103685 · Cited by 17
Cost in the United States of FDA-approved small molecule protein kinase inhibitors used in the treatment of neoplastic and non-neoplastic diseases
Roskoski, R. J. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.107036 · Cited by 19
Sulfonamide based pyrimidine derivatives combating Plasmodium parasite by inhibiting falcipains-2 and falcipains-3 as antimalarial agents
Rahman, A., Anjum, S., Bhatt, J. D., Dixit, B. C., Singh, A., khan, S., Fatima, S., Patel, T. S., & Hoda, N. (2024) · RSC Advances · doi:10.1039/d4ra04370g · Cited by 18
Non-systemic Intestine-Targeted Drugs
Fyfe, M. C. T. (2016) · Progress in medicinal chemistry · doi:10.1016/bs.pmch.2015.10.001 · Cited by 17
Synthesis, characterization and tumor inhibitory activity of a novel Pd( ii ) complex derived from methanethiol-bridged (2-((1 H -benzo[ d ]imidazol-2-yl)methylthio)-1 H -benzo[ d ]imidazol-6-yl)(phenyl)methanone
Sunil Kumar, N., Krishnamurthy, G., Bodke, Y. D., Malojirao, V. H., R., R. N. T., Kandagalla, S., & Prabhakar, B. T. (2018) · New Journal of Chemistry · doi:10.1039/c8nj03057j · Cited by 17
Structure-based screening of natural product libraries in search of potential antiviral drug-leads as first-line treatment to COVID-19 infection
Rao, S. J. A., & Shetty, N. P. (2022) · Microbial Pathogenesis · doi:10.1016/j.micpath.2022.105497 · Cited by 19
Overview of DNA repair pathways, current targets, and clinical trials bench to clinic
Kelley, M. R., & Fishel, M. L. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-803582-5.00001-2 · Cited by 18
Diversity‐Oriented Synthesis of Complex Pyrrole‐Based Architectures from Very Simple Starting Materials
Leonardi, M., Estévez, V., Villacampa, M., & Menéndez, J. C. (2019) · Advanced Synthesis & Catalysis · doi:10.1002/adsc.201900044 · Cited by 18
Identification of new potential cyclooxygenase-2 inhibitors: insight from high throughput virtual screening of 18 million compounds combined with molecular dynamic simulation and quantum mechanics
Saremi, L. H., Ebrahimi, A., & Lagzian, M. (2020) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2020.1737574 · Cited by 17
Rational Structure-Based Drug Design
Khanna, V., Ranganathan, S., & Petrovsky, N. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-809633-8.20275-6 · Cited by 16
Bioavailability predictions, pharmacokinetics and drug-likeness of bioactive compounds from Andrographis paniculata using Swiss ADME
Khare, S., Chatterjee, T., Gupta, S. K., & Ashish, P. (2023) · MGM Journal of Medical Sciences · doi:10.4103/mgmj.mgmj_245_23 · Cited by 20
Improving the Accuracy of Permeability Data to Gain Predictive Power: Assessing Sources of Variability in Assays Using Cell Monolayers
Pires, C. L., & Moreno, M. J. (2024) · Membranes · doi:10.3390/membranes14070157 · Cited by 17
Durian: A Comprehensive Benchmark for Structure-Based 3D Molecular Generation
Nie, D., Zhao, H., Zhang, O., Weng, G., Zhang, H., Jin, J., Lin, H., Huang, Y., Liu, L., Li, D., et al. (2024) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.4c02232 · Cited by 18
Allostery
Montserrat‐Canals, M., Cordara, G., & Krengel, U. (2025) · Quarterly Reviews of Biophysics · doi:10.1017/s0033583524000209 · Cited by 19
“Several allosteric effectors fit the profile of ‘ beyond the Rule of Five ’ (Doak et al., 2014; Lipinski, 2016; Doak and Kihlberg, 2017) (bRo5) molecules, an extension of the Lipinski ’ s ‘ rule of five ’ (Lipinski et al., 1997) (Ro5), a set of requirements on drug absorption and permeability.”
Bulk Measurement of Membrane Permeability for Random Cyclic Peptides in Living Cells to Guide Drug Development
Nielsen, A. L., Bartling, C. R. O., Zarda, A., Sadeleer, N. D., Neeser, R. M., Schwaller, P., Strømgaard, K., & Heinis, C. (2025) · Angewandte Chemie International Edition · doi:10.1002/anie.202500493 · Cited by 19
Forces Driving a Magic Bullet to Its Target: Revisiting the Role of Thermodynamics in Drug Design, Development, and Optimization
Minetti, C. A. S. A., & Remeta, D. P. (2022) · Life · doi:10.3390/life12091438 · Cited by 15
“In view of these developments, suggestions to expand such limits have been considered and a modified version designated as beyond Ro5 (bRo5) proposed [69].”
Background
Compounds in Indonesian Ginger Rhizome Extracts and Their Potential for Anti-Skin Aging Based on Molecular Docking
Asoka, S. F., Batubara, I., Lestari, A. R., Wahyuni, W. T., & Wahyudi, S. T. (2022) · Cosmetics · doi:10.3390/cosmetics9060128 · Cited by 16
Unusual Biotransformation Reactions of Drugs and Drug Candidates
Isin, E. M. (2023) · Drug Metabolism and Disposition · doi:10.1124/dmd.121.000744 · Cited by 16
Complexity‐to‐Diversity and Pseudo‐Natural Product Strategies as Powerful Platforms for Deciphering Next‐Generation Therapeutics
Alkubaisi, B. O., Shahin, A. I., Zenati, R. A., Ravi, A., Alchami, R., Alkalla, M., Khaled, R., El-Gamal, M. I., & Al‐Tel, T. H. (2023) · ChemMedChem · doi:10.1002/cmdc.202300117 · Cited by 17
Synthesis, Biological Activity, ADME and Molecular Docking Studies of Novel Ursolic Acid Derivatives as Potent Anticancer Agents
Michalak, O., Cybulski, M., Szymanowski, W., Gornowicz, A., Kubiszewski, M., Ostrowska, K., Krzeczyński, P., Bielawski, K., Trzaskowski, B., & Bielawska, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24108875 · Cited by 16
“In general, all estimated properties fell within the extended Lipinski’s rule of ﬁve spaces with some rare exceptions (such as the log p value > 8) that were only slightly beyond this rule [52].”
Background
Not all benzimidazole derivatives are microtubule destabilizing agents
Song, I., Park, S. J., Yeom, G. S., Song, K., Kim, T., & Nimse, S. B. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114977 · Cited by 16
First protein drug target’s appraisal of lead-likeness descriptors to unfold the intervening chemical space
Athar, M., Lone, M. Y., & Jha, P. C. (2017) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2016.12.019 · Cited by 16
Cannabinoid Type 1 Receptor (CB1) Ligands with Therapeutic Potential for Withdrawal Syndrome in Chemical Dependents of Cannabis sativa
Ferreira, J. V., Chaves, G. A., Marino, B. L. B., Sousa, K. P. A., de Souza, L. R., Brito, M. D. F. D. B., Teixeira, H. R. C., da Silva, C. H. T. D. P., Santos, C. B. R., & Hage-Melim, L. I. D. S. (2017) · ChemMedChem · doi:10.1002/cmdc.201700129 · Cited by 16
Exploiting intramolecular hydrogen bonding for the highly (Z)-selective & metal free synthesis of amide substituted β-aminoenones
Subramaniam, P., Ramasubbu, C., & Athiramu, S. (2017) · Green Chemistry · doi:10.1039/c7gc00909g · Cited by 16
Recent applications of covalent chemistries in protein–protein interaction inhibitors
Chan, A. M., Goodis, C. C., Pommier, E. G., & Fletcher, S. (2022) · RSC Medicinal Chemistry · doi:10.1039/d2md00112h · Cited by 17
Autonomous Untethered Microinjectors for Gastrointestinal Delivery of Insulin
Ghosh, A., Liu, W., Li, L., Pahapale, G. J., Choi, S. Y., Xu, L., Huang, Q., Zhang, R., Zhong, Z., Selaru, F. M., et al. (2022) · ACS Nano · doi:10.1021/acsnano.2c05098 · Cited by 16
Synthesis, characterization, electrochemistry, biological and molecular docking studies of the novel Co(II), Ni(II) and Cu(II) complexes derived from methanethiol bridged (2-((1H-benzo[d]imidazol-2-yl)methylthio)-1H-benzo[d]imidazol-6-yl)(phenyl)methanone
Kumar, N. S., Krishnamurthy, G., Somegowda, M., Pari, M., Naik, T. R. R., Kumara, K. S. J., Naik, S., Kandagalla, S., & Naik, N. (2020) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2020.128586 · Cited by 16
Leveraging nitrogen occurrence in approved drugs to identify structural patterns
Masand, V. H., Al‐Hussain, S. A., Alzahrani, A. Y. A., El-Sayed, N. N. E., Yeo, C. I., Tan, Y. S., & Zaki, M. E. A. (2023) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2023.2266990 · Cited by 15
Structure-activity relationships of middle-size cyclic peptides, KRAS inhibitors derived from an mRNA display
Kage, M., Hayashi, R., Matsuo, A., Tamiya, M., Kuramoto, S., Ohara, K., Irie, M., Chiyoda, A., Takano, K., Ito, T., et al. (2024) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2024.117830 · Cited by 15
Closing the Design–Make–Test–Analyze Loop: Interplay between Experiments and Predictions Drives PROTACs Bioavailability
Valencia, Z. S., Kingston, J. L. T., Miljković, F. N., Rowbottom, H., Mann, N., Davies, S., Ekblad, M., Castro, S. D., Kwapień, K., Malmerberg, E., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01642 · Cited by 16
Rifampicin as an example of beyond-rule-of-5 compound: Ionization beyond water and lipophilicity beyond octanol/water
Ermondi, G., Vallaro, M., Saame, J., Toom, L., Leito, I., Ruiz, R., & Caron, G. (2021) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2021.105802 · Cited by 15
A primer on natural product-based virtual screening
Koulouridi, E., Valli, M., Ntie‐Kang, F., & Bolzani, V. D. S. (2019) · Physical Sciences Reviews · doi:10.1515/psr-2018-0105 · Cited by 15
“Considering the aforementioned, attention should be paid during the filtering process of virtual NPs libraries of the limits applied in order to obtain compounds with desirable values of physicochemical properties, especially in the process of lead identification [184, 185].”
Background
Exploring Dolichos lablab compounds as potential inhibitors for fusion (F) protein of human metapneumovirus (HMPV): A systematic computational approach
Hossain, M. M., Apu, M. J. H., Aziz, M. F. B. A., Tanjil, M. T. R., Das, L. C., Kar, A., Evamoni, F. Z., & Morshed, M. M. (2025) · PLoS ONE · doi:10.1371/journal.pone.0332170 · Cited by 14
“Number of Rotatable Bonds (nrotb) evaluated as low Flexibility (nrotb ≤ 5), which is common in small, rigid molecules with good oral bioavailability, moderate Flexibility (5 < nrotb ≤ 10), and high Flexibility (nrotb > 10) [54].”
In vivo synthetic chemistry of proteolysis targeting chimeras (PROTACs)
Tomoshige, S., & Ishikawa, M. (2021) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2021.116221 · Cited by 17
Molecular Multi-Target Approach for Human Acetylcholinesterase, Butyrylcholinesterase and β-Secretase 1: Next Generation for Alzheimer’s Disease Treatment
Mendes, G. O., Pita, S. S. D. R., de Carvalho, P. B., da Silva, M. P., Taranto, A. G., & Leite, F. H. A. (2023) · Pharmaceuticals · doi:10.3390/ph16060880 · Cited by 14
“However, analyses carried out by [77], on a set of compounds in addition to the chemical space proposed by the rules of Lipinski and Veber, demonstrated that they were orally bioavailable.”
Naturally Occurring Hair Growth Peptide: Water-Soluble Chicken Egg Yolk Peptides Stimulate Hair Growth Through Induction of Vascular Endothelial Growth Factor Production
Nakamura, T., Yamamura, H., Park, K., Pereira, C., Uchida, Y., Noriko, H., Kim, M., & Itami, S. (2018) · Journal of Medicinal Food · doi:10.1089/jmf.2017.4101 · Cited by 15
“28 Hence, hydrolyzed smaller sizes of peptide of HGP should be effector(s) that stimulate VEGF production and hair growth.”
Synthesis and evaluation of 2‐aryl‐1 H ‐benzo[d]imidazole derivatives as potential microtubule targeting agents
Lee, J., Song, I., Warkad, S. D., Yeom, G. S., Shinde, P. B., Song, K., & Nimse, S. B. (2022) · Drug Development Research · doi:10.1002/ddr.21909 · Cited by 14
“The properties, including aqueous solubility (log S), skin permeability (log Kp), drug-likeness, percentage absorption, pharmacokinetics, and synthetic accessibility score (SA), were determined (Doak et al., 2014).”
Background
Why We Need to Implement Intramolecular Hydrogen-Bonding Considerations in Drug Discovery
Caron, G., & Ermondi, G. (2016) · Future Medicinal Chemistry · doi:10.4155/fmc-2016-0195 · Cited by 14
Novel hydroxamic acids incorporating 1-((1H-1,2,3-Triazol-4-yl)methyl)-3-hydroxyimino-indolin-2-ones: synthesis, biological evaluation, and SAR analysis
Dung, D. T. M., Pham‐The, H., Anh, D. T., Le‐Thi‐Thu, H., Yen, N. T. K., Han, B. W., Park, E. J., Choi, Y. J., Kang, J. S., Huệ, V. T. M., et al. (2018) · Journal of Chemical Sciences · doi:10.1007/s12039-018-1472-x · Cited by 14
Macrocycle modeling in ICM: benchmarking and evaluation in D3R Grand Challenge 4
Lam, P. C. ‐., Abagyan, R. A., & Totrov, M. M. (2019) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-019-00225-9 · Cited by 14
Can small drugs predict the intrinsic aqueous solubility of ‘beyond Rule of 5’ big drugs?
Avdeef, A., & Kansy, M. (2020) · ADMET & DMPK · doi:10.5599/admet.794 · Cited by 14
“Since 2014, an increasing number of ‘beyond the Rule of 5’ (bRo5) commentaries have stressed that the strict adherence to the Ro5 may result in lost opportunities [21-30].”
Background
A combined in silico and MD simulation approach to discover novel LpxC inhibitors targeting multiple drug resistant Pseudomonas aeruginosa
Alanazi, A., Younas, S., Khan, M. U., Saleem, H., Alruwaili, M., Abdalla, A. E., Mazhari, B. B. Z., Abosalif, K. O. A., & Ejaz, H. (2025) · Scientific Reports · doi:10.1038/s41598-025-99215-1 · Cited by 13
“In this study, a unique ligand, PubChem CID 59,323,957, was chosen as a reference compound for virtual screening.”
Influential
Polymorphic Structure Determination of the Macrocyclic Drug Paritaprevir by MicroED
Bu, G., Danelius, E., Wieske, L. H. E., & Gonen, T. (2024) · Advanced Biology · doi:10.1002/adbi.202300570 · Cited by 13
“[9, 10] Due to the conformational flexibility of macrocyclic drugs, they are prone to be crystallized as polymorphs.”
Background
Exploration of Potent Human α ‐Glucosidase Inhibitors Using In Silico Approaches: Molecular Docking, DFT, Molecular Dynamics Simulations, and MMPBSA
Bashyal, J., Raut, B. K., Upadhyaya, S. R., Sharma, K., & Parajuli, N. (2024) · Journal of Chemistry · doi:10.1155/2024/2086167 · Cited by 13
Identification of lead inhibitors for 3CLpro of SARS-CoV-2 target using machine learning based virtual screening, ADMET analysis, molecular docking and molecular dynamics simulations
Chhetri, S. P., Bhandari, V. S., Maharjan, R., & Lamichhane, T. R. (2024) · RSC Advances · doi:10.1039/d4ra04502e · Cited by 13
Virtual screening of potential orally active anti-bacterial compounds of finger millet
Jha, R. K., Shukla, A. K., Kumari, A., & Kumar, A. (2024) · Vegetos · doi:10.1007/s42535-024-01051-7 · Cited by 13
“Most of the bioactive compounds come from NPs that have strong potential to follow the theoretical rule of oral drug likeliness such as the Lipinski rule of five, Ghose rule, and other theoretical rules (Doak et al. 2014).”
Molecular Docking of Active Compounds from Traditional Medicinal Plants as ACE-2 protein (1R4L) inhibitor in searching for COVID-19 drug
Tungary, E., Ongko, J., Sukweenadhi, J., & Antonius, Y. (2022) · Research Journal of Pharmacy and Technology · doi:10.52711/0974-360x.2022.00712 · Cited by 13
In silico screening of phenylethanoid glycosides, a class of pharmacologically active compounds as natural inhibitors of SARS-CoV-2 proteases
Cheohen, C. F. D. A. R., Esteves, M. E. A., da Fonseca, T. S., Leal, C. M., Assis, F. D. L. F., Campos, M. F., Rebelo, R. S., Allonso, D., Leitão, G. G., da Silva, M. L., et al. (2023) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2023.02.020 · Cited by 13
“[73], new rules such as bRo5 (beyond the rule of 5) allow the identification of promising drugs that do not fit to the traditional one, for example, the HCV and HIV protease inhibitors, Simeprevir and Atazanavir, respectively.”
New nitrosyl ruthenium complexes with combined activities for multiple cardiovascular disorders
Júnior, F. S. G., Silveira, J. A. D. M., Holanda, T. M., Marinho, A. D., Ridnour, L. A., Wink, D. A., de Siqueira, R. J. B., Monteiro, H. S. A., Sousa, E. H. S., & Lopes, L. G. D. F. (2023) · Dalton Transactions · doi:10.1039/d3dt00059a · Cited by 13
Mirror image pairs of cyclic hexapeptides have different oral bioavailabilities and metabolic stabilities
Lohman, R., Nielsen, D. S., Kok, W. M., Hoang, H. N., Hill, T. A., & Fairlie, D. P. (2019) · Chemical Communications · doi:10.1039/c9cc06234c · Cited by 13
Transition from Amorphous Cyclosporin A Nanoparticles to Size-Reduced Stable Nanocrystals in a Poloxamer 407 Solution
Chen, Z., Higashi, K., Ueda, K., & Moribe, K. (2021) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.1c00721 · Cited by 13
Structure, solubility, and permeability relationships in a diverse middle molecule library
Miyachi, H., Kanamitsu, K., Ishii, M., Watanabe, E., Katsuyama, A., Otsuguro, S., Yakushiji, F., Watanabe, M., Matsui, K., Sato, Y., et al. (2021) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2021.127847 · Cited by 12
A two-faced selectivity solution to target SMARCA2 for cancer therapy
Harling, J. D., & Tinworth, C. P. (2023) · Nature Communications · doi:10.1038/s41467-023-36238-0 · Cited by 12
Promising Antifungal Molecules against Mucormycosis Agents Identified from Pandemic Response Box®: In Vitro and In Silico Analyses
Xisto, M. I. D. D. S., Rollin‐Pinheiro, R., de Castro-Almeida, Y., dos Santos, G. M. P., Rochetti, V. P., Borba-Santos, L. P., Fontes, Y. D. S., Ferreira‐Pereira, A., Rozental, S., & Barreto‐Bergter, E. (2023) · Journal of Fungi · doi:10.3390/jof9020187 · Cited by 12
“Additionally, although MW plays an important role in determining the permeability of drugs across the intestinal membrane [55], a small number of approved oral drugs are beyond the chemical space defined by Ro5 (bRoF) and possess a high MW, such as isavuconazonium, an oral prodrug of isavuconazole [50,56,57].”
Background
Controlling the Chameleonic Behavior and Membrane Permeability of Cyclosporine Derivatives via Backbone and Side Chain Modifications
Lee, D., Choi, J., Yang, M. J., Park, C., & Seo, J. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01140 · Cited by 12
Machine learning‐guided design of potent darunavir analogs targeting HIV ‐1 proteases: A computational approach for antiretroviral drug discovery
Chuntakaruk, H., Boonpalit, K., Kinchagawat, J., Nakarin, F., Khotavivattana, T., Aonbangkhen, C., Shigeta, Y., Hengphasatporn, K., Nutanong, S. Y., Rungrotmongkol, T., et al. (2024) · Journal of Computational Chemistry · doi:10.1002/jcc.27298 · Cited by 12
Discovery of a nitroaromatic nannocystin with potent in vivo anticancer activity against colorectal cancer by targeting AKT1
Zhang, H., Xie, F., Yuan, X., Dai, X.-T., Tian, Y., Sun, M.-M., Yu, S., Cai, J., Sun, B., Zhang, W., et al. (2024) · Acta Pharmacologica Sinica · doi:10.1038/s41401-024-01231-w · Cited by 12
“Macrocycles possess a distinct large ring architecture situated in the beyond the rule of 5 (bRo5) chemical space [41 – 45], as such capable of modulating dif ﬁ cult therapeutic targets [46 – 48] and indeed having emerged as a privileged class of targeted antineoplastic drugs [49, 50].”
Systematic Determination of the Impact of Structural Edits on Peptide Accumulation into Mycobacteria
Dash, R., Liu, Z., Lepori, I., Chordia, M. D., Ocius, K. L., Holsinger, K. A., Zhang, H., Kenyon, R., Im, W., Siegrist, M. S., et al. (2025) · ACS Chemical Biology · doi:10.1021/acschembio.5c00330 · Cited by 10
Prediction and interpretation of the lipophilicity of small peptides
Visconti, A., Ermondi, G., Caron, G., & Esposito, R. (2015) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-015-9829-4 · Cited by 12
“discovery process has to be adapted to peptidic structures [4–6].”
Background
Influence of FcRn binding properties on the gastrointestinal absorption and exposure profile of Fc molecules
Lawrence, S. A., Blankenship, R. L., Brown, R. M., Estwick, S. A., Ellis, B., Thangaraju, A., & Datta‐Mannan, A. (2020) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2020.115942 · Cited by 12
Quinoline‐Dihydropyrimidin‐2(1H)‐one Hybrids: Synthesis, Biological Activity, and Mechanistic Studies
Parth, Kaur, H., Persoons, L., Andreï, G., & Singh, K. (2022) · ChemMedChem · doi:10.1002/cmdc.202200031 · Cited by 12
Synthesis of Pyridazine-Based α-Helix Mimetics
Londregan, A. T., Piotrowski, D. W., & Wei, L. (2016) · ACS Combinatorial Science · doi:10.1021/acscombsci.6b00111 · Cited by 12
Medicines discovery for auditory disorders: Challenges for industry
Cousins, R. P. C. (2019) · The Journal of the Acoustical Society of America · doi:10.1121/1.5132706 · Cited by 12
In silico predictions on the possible mechanism of action of selected bioactive compounds against breast cancer
Muhammad, A. I., Katsayal, B. S., Forcados, G. E., Malami, I., Abubakar, I. B., kandi, A. I., Idris, A. M., Yusuf, S., Musa, S. M., Monday, N., et al. (2020) · In Silico Pharmacology · doi:10.1007/s40203-020-00057-8 · Cited by 12
Synthesis of novel isoflavone/benzo-δ-sultam hybrids as potential anti-inflammatory drugs
Menghereş, G., Rice, C. R., Olajide, O. A., & Hemming, K. (2020) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2020.127761 · Cited by 12
A membrane permeability database for nonpeptidic macrocycles
Feng, Q., Chavez, D. D., Kihlberg, J. O., & Poongavanam, V. (2025) · Scientific Data · doi:10.1038/s41597-024-04302-z · Cited by 12
Self-citation
Elucidating the Potential Inhibitor against Type 2 Diabetes Mellitus Associated Gene of GLUT4
Aldahish, A. A., Balaji, P., Vasudevan, R., Kandasamy, G., James, J. P., & Prabahar, K. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13040660 · Cited by 11
“Molecules violating more than one of these rules may have problems with bioavailability [53].”
Background
Development of Potent Mcl-1 Inhibitors: Structural Investigations on Macrocycles Originating from a DNA-Encoded Chemical Library Screen
Hekking, K. F. W., Maroto, S., van Kekem, K., Haasjes, F. S., Slootweg, J. C., Alink, P. G. B. O., Dirks, R. P., Sardana, M., Bolster, M. G., Kuijpers, B. H. M., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c02206 · Cited by 12
Small Natural Cyclic Peptides from DBAASP Database
Alimbarashvili, E., Samsonidze, N., Grigolava, M., & Pirtskhalava, M. (2024) · Pharmaceuticals · doi:10.3390/ph17070845 · Cited by 11
Discovery of Indole–Thiourea Derivatives as Tyrosinase Inhibitors: Synthesis, Biological Evaluation, Kinetic Studies, and In Silico Analysis
Xu, Y., Liang, X., & Hyun, C. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25179636 · Cited by 11
“Both co-crystallized ligands bound to the same site on their respective proteins with minimal conformational differences, achieving RMSD values that were lower than the widely The results indicated that all synthesized ligands displayed favorable binding energy values and effectively interacted…”
Background

Authors: Doak, B. C., Over, B., Giordanetto, F., & Kihlberg, J.
Affiliations: Uppsala University (SE)
Corresponding author: Kihlberg, Jan
ORCID: Doak, Bradley Croy
Giordanetto, Fabrizio
Kihlberg, Jan
Venue: Chemistry & Biology
Publisher: Elsevier BV
Published: 2014-09
Volume: 21
Issue: 9
Pages: 1115-1142
ISSN: 1074-5521 (ISSN-L)
DOI: 10.1016/j.chembiol.2014.08.013
OpenAlex: W2106605095
Cited by: 835
References: 295
Citations by year: 2026: 101 · 2025: 82 · 2024: 103 · 2023: 111 · 2022: 103 · 2021: 88 · 2020: 65 · 2019: 50 · 2018: 51 · 2017: 27 · 2016: 37 · 2015: 14
FWCI: 2.15
Type: journal article
Language: en
Open access: hybrid
doi.org
Licence: public-domain
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor, 382 d)
Locations: Chemistry & Biology (publishedVersion, public-domain)
PubMed (publishedVersion)
Funders: AstraZeneca
Uppsala Universitet
Topics: Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Drug Solubulity and Delivery Systems
Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
Keywords: Rule of 5, oral bioavailability, drug discovery, molecular weight, intramolecular hydrogen bonding, macrocyclization, oral dosage forms, natural products, structure-based drug design, pharmacokinetics, clinical candidates
MeSH terms: Administration, Oral, Biological Products, Pharmaceutical Preparations, Humans, Molecular Weight, Protease Inhibitors, Databases, Factual, Drug Delivery Systems, Macrocyclic Compounds, Drug Discovery

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Oral Druggable Space beyond the Rule of 5: Insights from Drugs and Clinical Candidates

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks